Knowing the Market

Research executed on healthy, premenopausal women in the Netherlands specified that Yaz, Yasmin, and Ocella (generic Yasmin) suffered an enhanced risk of venous thrombosis as compared to non-users. The risks were increased as high as five times with oral contraceptives. These studies were published in August 2009. This was just the beginning of the controversy surrounding Yaz, Yasmin, and Ocella and the accompanying lawsuits to come involving Yaz side effects.

Among the other contestations impending on Yasmin, Yaz and Ocella birth control, the pills also include drospirenone, an element not in other oral contraceptives. The British Medical Journal published studies in August 2009 diplaying an increased risk of venous blood clots in young women taking drospirenone as opposed to those who used other oral contraceptives. In that same month, the FDA issued an unconnected advisory to Bayer Pharmaceuticals, makers of Yasmin, for using low-quality batches of drospirenone from a plant in Germany. For the benefit of public interest and wellbeing, these studies have been made available free online.

Women taking Yasmin, Yaz or Ocella to avoid getting pregnant or to treat PMDD (Premenstrual Dysphoric Disorder) or severe acne have reportedly suffered serious injury to their health and wellbeing. Although not all pharmaceuticals are one-hundred percent safe, the main topic surrounding Yaz seems to be that the original commercials downplayed the health risks and side effects. This attracted users to the product that may not have taken it otherwise had they been properly informed about the risks posed by Ocella, Yasmin and Yaz.